Can a new drug shield nerves from Chemotherapy's side effects?

NCT ID NCT07765446

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a common side effect causing pain, numbness, and tingling. Participants will receive one of three doses of SIR2501, and researchers will monitor side effects and drug levels in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SIR2501
What this could lead to
If successful, SIR2501 could offer a way to prevent or reduce the nerve pain and numbness caused by paclitaxel chemotherapy, improving quality of life for cancer patients.
What could go wrong
This is a small, early-phase study focused on safety and dosing, so it may not prove effective. The drug could also have side effects or fail to show a clear benefit in preventing neuropathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Study site

    Baltimore, Maryland, 21287, United States

  • Study site

    East Brunswick, New Jersey, 08816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.